Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.

SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood (2011) 1.11

IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. PLoS One (2014) 0.98

Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis (2014) 0.91

Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother (2012) 0.89

Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J Acquir Immune Defic Syndr (2009) 0.85

Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS (2017) 0.84

Cellular immune responses in human immunodeficiency virus (HIV)-1-infected children: is immune restoration by highly active anti-retroviral therapy comparable to non-progression? Clin Exp Immunol (2011) 0.76

[Persistence of hepatitis A virus antibodies after primary immunization and response to revaccination in children and adolescents with perinatal HIV exposure]. Rev Paul Pediatr (2015) 0.75

Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med (2001) 6.01

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 3.45

Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96

Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.37

ELISA for the routine determination of antitoxic immunity to tetanus. J Biol Stand (1986) 1.32

Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J (2003) 1.24

Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis (2005) 1.18

Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS (2002) 1.14

Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS (1999) 1.11

Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS (2000) 1.07

Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics (2003) 0.98

Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis (2004) 0.97

Cell-mediated and humoral immune responses in children infected with human immunodeficiency virus during the first four years of life. J Pediatr (1992) 0.93

Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 0.92

Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS (2001) 0.91

Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). Eur J Pediatr (2006) 0.89

Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis (2002) 0.83

Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis (2005) 0.83

Correlation of clinical parameters and immunological function with human immunodeficiency virus plasma viremia in children. Viral Immunol (1999) 0.82

Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol (2005) 0.80

Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12

Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis (2004) 5.93

Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis (2012) 4.60

Pregnancy and infection. N Engl J Med (2014) 4.15

Reduced lopinavir exposure during pregnancy. AIDS (2006) 3.98

Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med (2010) 3.81

Influenza vaccination of pregnant women and protection of their infants. N Engl J Med (2014) 3.68

Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med (2011) 3.29

Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA (2002) 2.93

Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet (2013) 2.64

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50

Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr (2008) 2.38

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep (2009) 2.31

Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics (2007) 2.08

Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet (2003) 2.04

Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J (2008) 2.00

Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS (2006) 1.99

Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98

A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS (2006) 1.96

Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis (2003) 1.91

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS (2007) 1.70

Early immunological predictors of neurodevelopmental outcomes in HIV-infected children. Clin Infect Dis (2009) 1.68

Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2008) 1.65

Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel. J Infect Dis (2012) 1.60

Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS (2012) 1.59

Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus. J Infect Dis (2007) 1.59

Breast-feeding and Transmission of HIV-1. J Acquir Immune Defic Syndr (2004) 1.56

Pandemic influenza A H1N1 2009 infection versus vaccination: a cohort study comparing immune responses in pregnancy. PLoS One (2012) 1.55

Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr (2011) 1.55

Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia. AIDS Res Hum Retroviruses (2008) 1.52

Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis (2010) 1.52

Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. Pediatrics (2007) 1.51

Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis (2003) 1.50

Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024. AIDS (2005) 1.49

Predictors of repeat pregnancy among HIV-1-infected women. J Acquir Immune Defic Syndr (2007) 1.48

Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47

Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis (2009) 1.46

Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44

A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42

Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. American Academy of Pediatrics Committee on Pediatric AIDS. Pediatrics (2003) 1.41

Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39

Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis (2010) 1.39

The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol (2006) 1.37

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35

Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J (2005) 1.34

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2010) 1.33

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32

Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study. Am J Epidemiol (2008) 1.31

Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev (2009) 1.29

Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother (2006) 1.28

In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS (2011) 1.26

Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav (2010) 1.26

Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr (2011) 1.24

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine (2008) 1.24

HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis (2009) 1.24

Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. Horm Res Paediatr (2011) 1.23

Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J Immunol Methods (2010) 1.22

How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol (2005) 1.21

Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother (2007) 1.21

Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol (2009) 1.20

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (2011) 1.20

Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS (2012) 1.20

Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. J Allergy Clin Immunol (2011) 1.19

Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr (2005) 1.19

A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol (2012) 1.17

Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis (2006) 1.17

Use of PCR for the diagnosis of herpesvirus infections of the central nervous system. J Clin Virol (2002) 1.17

HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS (2006) 1.15

Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia. Sex Transm Dis (2006) 1.13

Bone mineral density in children and adolescents with perinatal HIV infection. AIDS (2013) 1.13

Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS (2008) 1.13

Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe. Clin Infect Dis (2003) 1.13

Impact of partner abuse on women's reproductive lives. J Am Med Womens Assoc (2005) 1.11

Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. J Immunol (2004) 1.11

Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis (2003) 1.11

Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr (2010) 1.10

Predictors of stillbirth in sub-saharan Africa. Obstet Gynecol (2007) 1.10

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother (2011) 1.09

Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr (2011) 1.08

Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics (2007) 1.08

Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother (2004) 1.08

Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J (2012) 1.06

A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J (2009) 1.06

Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood (2008) 1.06

History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls. Am J Epidemiol (2005) 1.05

Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr (2010) 1.05

A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J (2010) 1.05

Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS (2007) 1.04

Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the women and infants transmission study. Pediatr Infect Dis J (2005) 1.04

Mode of delivery and postpartum morbidity in Latin American and Caribbean countries among women who are infected with human immunodeficiency virus-1: the NICHD International Site Development Initiative (NISDI) Perinatal Study. Am J Obstet Gynecol (2006) 1.04

Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women. Am J Clin Nutr (2008) 1.04

Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir Ther (2011) 1.02

Participation of HIV-infected pregnant women in research in the United States. AIDS Res Hum Retroviruses (2007) 1.02

Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics (2007) 1.02